Stephen Laviers

Investement Banking

Bryan, Garnier & Co, a leading pan-European investment bank focusing on growth companies, is delighted to announce that Stephen Laviers has been appointed as Managing Director in Investment Banking.

Stephen joined Bryan, Garnier & Co in May as Managing Director in the Energy Transition & Sustainability investment banking team.

Prior to joining Bryan, Garnier & Co, Stephen spent 3 years as Investment Banking & Resource Efficiency Lead at Cyan Finance, a London-based finance house for companies in the green, sustainable and socially positive economy. Before this, he spent over 12 years at UBS Investment Bank in both New York and London, as part of the Renewable Energy, Clean Technology & Resource Efficiency investment banking team. Stephen has extensive industry experience across numerous sub-verticals of the Energy Transition & Sustainability industry, including eMobility, energy storage, renewables generation, sustainable agriculture and smart consumer. Previously, Stephen spent 5 years in the International Capital Markets team of Allen & Overy in Paris.

With more than 60 private and public capital-raising and M&A transactions closed in 2020, Bryan, Garnier & Co benefits from longstanding leadership in the healthcare, technology, business services and environmental sectors in Europe. Over the past 36 months, Bryan, Garnier & Co has led more than 40 ECM transactions across nine countries, raising over EUR 2.5bn. Recent successes include the IPOs and/or follow-ons for HDF Energy (Euronext Paris), Mister SPEX (Deutsche Boerse), Carbios (Euronext Paris), Azelio (NASDAQ Stockholm), McPhy Energy (Euronext Paris), Linas Matkase (NASDAQ Stockholm), Heidelberg Pharma (Deutsche Börse), Swedish Stirling (NASDAQ Stockholm), Basilea (SIX) GenSight (Euronext Paris), and Valneva (NASDAQ / Euronext Paris).

Additional recent transactions include the acquisition of DL Software by TA Associates, the sale of smartTrade to leading software private equity investor Hg Capital, the take-private of ITSM player Easyvista by Eurazeo, capital for circular economy player asgoodasnew, the sale of Specim to Konica Minolta and the sale of BlueBee to Illumina. Over the years, Bryan, Garnier & Co has distinguished itself by backing some of the most disruptive companies in the domain of alternative proteins (Prolupin), green hydrogen (McPhy Energy), cannabis (Canopy Growth), 3D printing (Materialise), blockchain and cryptocurrencies (Bitfury Group), and mRNA biotech (Moderna and BioNTech).

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.

(www.bryangarnier.com)